MedTrace Logo

BR55 in Prostate Cancer: an Exploratory Clinical Trial

NCT01253213 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-08-01

No results posted yet for this study

Summary

The purpose of this study is to determine whether BR55 is able to identify areas of VEGFR2 expression in human prostate by ultrasound molecular imaging.

This will be compared with histopathology analysis (location based on expression of VEGFR2 in tissue specimens determined by immuno-histochemistry, IHC).

Conditions

Interventions

DRUG

BR55

One to two bolus (2nd bolus optional) of BR55 per patient

Sponsors & Collaborators

  • Bracco Imaging S.p.A.

    collaborator INDUSTRY

  • Bracco Diagnostics, Inc

    lead INDUSTRY

Principal Investigators

  • Hessel Wijkstra, Dr. · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01253213 on ClinicalTrials.gov